Sentiment Trading

Camurus AB has reported a strong first quarter, exceeding market expectations and defying market uncertainty, with a new CFO appointment set to steer the company through its next phase of growth.

Camurus AB, a Swedish biotech company, has received a positive recommendation from the European Medicines Agency for its innovative drug Oczyesa, positioning the company for growth and expansion in the pharmaceutical sector.